Opioid receptor modulation of hedonic taste preference and food intake: A single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 464-474

  Nathan, Pradeep J ^a,b   O'Neill, Barry V ^a,b   Bush, Mark A ^a   Koch, Annelize ^a   Tao, Wenli X ^a   Maltby, Kay ^a   Napolitano, Antonella ^a   Brooke, Allison C ^a   Skeggs, Andrew L ^a   Herman, Craig S ^a   Larkin, Andrew L ^a   Ignar, Diane M ^a   Richards, Duncan B ^a   Williams, Pauline M ^a   Bullmore, Edward T ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Opioid receptor; binge eating; food intake; hedonic; obesity; pharmacodynamic; pharmacokinetics; reward; taste preference

Indexed keywords

GSK 1521498; MU OPIATE RECEPTOR AGONIST; N [[3,5 DIFLUORO 3' (1H 1,2,4 TRIAZOL 3 YL) 4 BIPHENYLYL]METHYL] 2,3 DIHYDRO 1H INDEN 2 AMINE PHOSPHATE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; COMPULSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAIRY PRODUCT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ECG ABNORMALITY; FAT INTAKE; FATIGUE; FOOD INTAKE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INGESTION; MALADJUSTMENT; MALE; MUSCLE FATIGUE; NAUSEA; NORMAL HUMAN; OBESITY; OVERNUTRITION; PALATABILITY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REWARD; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; SUGAR INTAKE; SYSTOLIC BLOOD PRESSURE; TASTE PREFERENCE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INVERSE AGONISM; EATING; FOOD PREFERENCES; HUMANS; INDANS; MALE; RECEPTORS, OPIOID, MU; SINGLE-BLIND METHOD; TRIAZOLES;

EID: 84859010444     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011399577     Document Type: Article

References (51)

1. Reid LD. Endogenous opioid peptides and regulation of feeding and drinking. Am J Clin Nutr. 1985;42:1099-1132. (Pubitemid 16148064)
2. Berridge KC. Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev. 1996;20:1-25. (Pubitemid 126682107)
3. Levine AS, Billington CJ. Why dowe eat? A neural systems approach. Annu Rev Nutr. 1997;17:597-619. (Pubitemid 27328814)
4. Zhang M, Kelley AE. Enhanced intake of high-fat food following striatal mu-opioid stimulation: microinjection mapping and fos expression. Neuroscience. 2000;99:267-277. (Pubitemid 30628414)
5. Zhang M, Gosnell BA, Kelley AE. Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. J Pharmacol Exp Ther. 1998;285:908-914. (Pubitemid 28237478)
6. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci. 2002;22:3306-3311. (Pubitemid 37465733)
7. Baldo BA, Kelley AE. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacolog. 2007;191:439-459. (Pubitemid 46355910)
8. Nathan PJ, Bullmore ET. From taste hedonics tomotivational drive: central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009;12:1-14.
9. Evans KR, Vaccarino FJ. Amphetamine- and morphine-induced feeding: evidence for involvement of reward mechanisms. Neurosci Biobehav Rev. 1990;14:9-22. (Pubitemid 20115609)
10. Bakshi VP, Kelley AE. Feeding induced byopioid stimulation of the ventral striatum: role of opiate receptor subtypes. J Pharmacol Exp Ther. 1993;265:1253-1260. (Pubitemid 23321027)
11. Majeed NH, Przewłocka B, Wedzony K, Przewłocki R. Stimulation offood intake following opioid microinjection into the nucleus accumbens septi in rats. Peptides. 1986;7:711-716. (Pubitemid 17182331)
12. Mucha RF, Iversen SD. Increased food intake after opioid microinjections into nucleus accumbens and ventral tegmental area of rat. Brain Res. 1986;397:214-224. (Pubitemid 17185811)
13. Zhang M, Kelley AE. Opiate agonists microinjected into the nucleus accumbens enhance sucrose drinking in rats. Psychopharmacology. 1997;132:350-360. (Pubitemid 27373476)
14. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav. 2002;76:365-377. (Pubitemid 34765590)
15. Will MJ, Franzblau EB, Kelley AE. Nucleus accumbens muopioids regulate intake of a high-fat diet via activation of a distributed brain network. J Neurosci. 2003;23:2882-2888. (Pubitemid 36418624)
16. Apfelbaum M, Mandenoff A. Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet. Pharmacol Biochem Behav. 1981;15:89-91. (Pubitemid 11083226)
17. Marks-Kaufman R, Kanarek RB. Modifications of nutrient selection induced by naloxone in rats. Psychopharmacology. 1981;74:321-324. (Pubitemid 11003749)
18. Marks-Kaufman R, Plager A, Kanarek RB. Central and peripheral modifications of endogenous opioid systems to nutrient selection in rats. Psychopharmacology. 1985;85:414-418. (Pubitemid 15075590)
19. Lynch WC, Libby L. Naloxone suppresses intake of highly preferred saccharin solutions in food deprived and sated rats. Life Sci. 1983;33:1909-1914. (Pubitemid 13010942)
20. Cooper SJ. Effects ofopiate agonists and antagonists on fluid intake and saccharin choice in the rat. Neuropharmacology. 1983;22:323-328. (Pubitemid 13144229)
21. Cooper SJ, Barber DJ, Barbour-McMullen J. Selective attenuation of sweetened milk consumption by opiate receptor antagonists in male and female rats of the Roman strains. Neuropeptides. 1985;5:349-352. (Pubitemid 15141563)
22. Cooper SJ, Turkish S. Effects of naltrexone on food preference and concurrent behavioral responses in food deprived rats. Pharmacol Biochem Behav. 1989;33:17-20. (Pubitemid 19202599)
23. Giraudo SQ, Grace MK, Welch CC, Billington CJ, Levine AS. Naloxone's anorectic effect isdependent upon the relative palatability of food. Pharmacol Biochem Behav. 1993;46:917-921.
24. Bodnar RJ, Glass MJ, Ragnauth A, Cooper ML. General, muand kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Res. 1995;700:205-212.
25. Levine AS, Weldon DT, Grace M, Cleary JP, Billington CJ. Naloxone blocks that portion of feeding driven by sweet taste in food-restricted rats. Am J Physiol. 1995;268:R248-R252.
26. Cleary J, Weldon DT, O'Hare E, Billington C, Levine AS. Naloxone effects onsucrose-motivated behavior. Psychopharmacology. 1996;126:110-114.
27. Kelley AE, Bless EP, Swanson CJ. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther. 1996;278:1499-1507. (Pubitemid 27167005)
28. Glass MJ, Grace MK, Cleary JP, Billington CJ, Levine AS. Naloxone's effect onmeal microstructure of sucrose and cornstarch diets. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1605-R1612.
29. Glass MJ, Briggs JE, Billington CJ, Kotz CM, Levine AS. Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala dynorphin gene expression. Am J Physiol Regul Integr Comp Physiol. 2002;283:R161-R167. (Pubitemid 34863921)
30. Pecina S, Berridge KC. Opioid site in nucleus accumbens shell mediates eating and hedonic 'liking' for food: map based on microinjection fos plumes. Brain Res. 2000;863:71-86. (Pubitemid 30201586)
31. Barbano MF, Cador M. Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behaviour by dopaminergic and opioidergic drugs. Neuropsychopharmacology. 2006;31:1371-1381.
32. Cottone P, Sabino V, Steardo L, Zorrilla EP. Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology. 2008;33:524-535.
33. Barbano MF, Le Saux M, Cador M. Involvement of dopamine and opioids in the motivation to eat: influence of palatability, homeostatic state, and behavioral paradigms. Psychopharmacology. 2009;203:475-487.
34. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002;26:713-728. (Pubitemid 35477576)
35. Arbisi PA, Billington CJ, Levine AS. The effect of naltrexone on taste detection and recognition threshold. Appetite. 1999;32:241-249. (Pubitemid 29176850)
36. Fantino M, Hosotte J, Apfelbaum M. An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol. 1986;251:R91-R96.
37. Yeomans MR, Wright P, Macleod HA, Critchley JA. Effects of nalmefene on feeding in humans: dissociation of hunger and palatability. Psychopharmacology. 1990;100:426-432. (Pubitemid 20052436)
38. Yeomans MR, Gray RW. Selective effects of naltrexone on food pleasantness and intake. Physiol Behav. 1996;60:439-446. (Pubitemid 26274284)
39. Yeomans MR, Wright P. Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite. 1991;16:249-259.
40. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav. 1992;51:371-379.
41. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Naloxone, anopiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995;61:1206-1212.
42. Ignar DM, Goetz AS, Noble K, Carballo L, et al. Regulation of ingestive behaviors by GSK 1521498, a μ-opioid receptor-selective inverse agonist. In press.
43. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;80:1-46.
44. McNair DM, Heuchert JP. Profile of Mood States: Technical Update. New York, NY: Multi-Health Systems; 2005.
45. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting anti-obesity drugs. CNS Neurosci Ther. 2010 Jul 7. [Epub ahead of print]
46. Feuerstein G, Sirén AL. Hypothalamic mu-opioid receptors in cardiovascular control: a review. Peptides. 1988;9(suppl 1):75-78.
47. Hill-Pryor C, Lindsey D, Lapanowski K, Dunbar JC. The cardiovascular responses tomu opioid agonist and antagonist in conscious normal and obese rats. Peptides. 2006;27:1520-1526. (Pubitemid 43767010)
48. Verebey K, Volavka J, Mulé SJ, Resnick RB. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20:315-328.
49. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1:219-230.
50. Dixon R, Gentile J, Hsu HB, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987;27:233-239. (Pubitemid 18026908)
51. Weerts EM, Kim YK, Wand GS, et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33:653-665.